Introduction
============

Type 2 diabetes (T2D) is a complex, multifactorial disorder characterized by chronic hyperglycemia due to the interplay of multiple genetic variants and several environmental factors. As a result of aging populations, and the increasing prevalence of obesity and physical inactivity, the number of patients with T2D has markedly increased worldwide ([@b1-mmr-13-05-3735]). The disease is considered a polygenic disorder, in which each genetic variant confers a partial and additive effect. Only 5--10% of T2D cases are due to single gene defects; these include maturity-onset diabetes of the young, insulin resistance syndromes, mitochondrial diabetes and neonatal diabetes ([@b2-mmr-13-05-3735]). Examining T2D susceptibility genes may be useful for the prediction, prevention and early treatment of the disease.

Following previous genome-wide association studies (GWAS), the number of replicated common genetic variants associated with T2D has rapidly increased ([@b3-mmr-13-05-3735]--[@b9-mmr-13-05-3735]). In addition, \>40 T2D-associated genetic loci have been identified, however, these loci have been revealed primarily on the basis of investigations of European individuals ([@b10-mmr-13-05-3735]). The identified genomes only explain a small proportion of the estimated heritability of T2D, suggesting that additional genetic factors remain to be identified. One limitation of GWAS is the large number of hypotheses and the high economic cost of these investigations ([@b11-mmr-13-05-3735]). Several studies have addressed the feasibility and effectiveness of pooling-based GWAS, with considerable savings in time and cost ([@b11-mmr-13-05-3735]--[@b13-mmr-13-05-3735]). Additionally, whole-genome sequencing across multiple samples in a population provides an unprecedented opportunity for comprehensively characterizing the polymorphic variants in the population ([@b14-mmr-13-05-3735]).

Although the genetic contribution to T2D is well recognized, there are now at least 19 loci containing genes, which are known to increase the risk of T2D, including PPARG, KCNJ11, KCNQ1, CDKAL1, CDKN2A-2B, CDC123-CAMK1D, MTNR1B, TCF7L2, TCF2 (HNF1B), HHEX-KIF11-IDE, JAZF1, IGF2BP2, SLC30A8, THADA, ADAMTS9, WFS1, FTO, NOTCH2 and TSPAN8 ([@b2-mmr-13-05-3735]). To date, the current set of 66 established susceptibility loci, identified primarily through large-scale GWAS ([@b2-mmr-13-05-3735],[@b8-mmr-13-05-3735],[@b15-mmr-13-05-3735]--[@b22-mmr-13-05-3735]), encompasses, at most, 10% of the familial aggregation of the disease. Of the currently established susceptibility loci, nine of the loci are contained in the 19 loci-containing genes. In the present study, the genomes of 100 Chinese patients with T2D and 100 non-diabetic Chinese individuals were examined using high throughput genome-wide re-sequencing and DNA pooling with Illumina HiSeq 2000 (Illumina, San Diego, CA, USA). The aim of the present study was to determine the rates of susceptibility genes in T2D in the Chinese population.

Materials and methods
=====================

Study populations
-----------------

The present study was performed between August 2012 and the end of June 2013 at the 181st Hospital of People\'s Liberation Army, (Guilin, China). A total of 200 Chinese individuals were recruited, of which half were diagnosed with T2D. All participants with T2D were unrelated, and their disease was defined by World Health Organization criteria ([@b23-mmr-13-05-3735]). The healthy individuals had a fasting plasma glucose \<5.6 mmol/l, a 2-h oral glucose tolerance test-based plasma glucose \<7.8 mmol/l, a body mass index \<27.5 kg/m^2^ and blood pressure \<140/90 mmHg, with no antihypertensive treatment. The clinical and biochemical characteristics of the 200 individuals are presented in [Table I](#tI-mmr-13-05-3735){ref-type="table"}.

Ethics
------

The present study was approved by the Medical and Health Research Ethics Committee of the 181st Hospital of the People\'s Liberation Army (Guilin, China). All participants provided informed consent for the use of their biological samples for genetic investigation.

Experimental procedure
----------------------

Peripheral blood samples from the 200 volunteers were collected for genomic DNA extraction. DNA preparation followed the manufacturer\'s protocol (Illumina). Genomic DNA was extracted and then randomly fragmented. Following electrophoresis, DNA fragments of desired length (90 bp) were gel purified using QIAquick PCR Purification kit (Qiagen GmbH, Hilden, Germany). Adapter ligation and DNA cluster preparation were performed as part of Solexa sequencing by Beijing Genomics Institute (Shenzhen, China) ([@b24-mmr-13-05-3735]--[@b26-mmr-13-05-3735]).

Bioinformatics analysis
-----------------------

The bioinformatics analysis used the sequencing data (raw data) generated from the Illumina HiSeq 2000. First, the adapter sequence in the raw data was removed, and low quality reads, which contained too many unknown bases (N) or low quality bases were discarded. This step produced \'clean data\'. Secondly, Burrows-Wheeler Aligner (BWA) ([@b27-mmr-13-05-3735]) was used to align the reads to the reference sequence. The alignment information was stored in BAM format files, which were further processed during subsequent steps, including fixing mate-pair information, adding read group information and marking duplicate reads caused by polymerase chain reaction (PCR). Following these processes, the final BAM files were ready for variant calling. Single nucleotide polymorphisms (SNPs) were detected using SOAPsnp ([@b28-mmr-13-05-3735]), small insertion/deletions (InDels) were detected using SAMtools ([@b29-mmr-13-05-3735])/GATK ([@b30-mmr-13-05-3735],[@b31-mmr-13-05-3735]), copy number variants (CNVs) were detected using CNVnator ([@b32-mmr-13-05-3735],[@b33-mmr-13-05-3735]), single nucleotide variants (SNVs) were detected using Varscan ([@b34-mmr-13-05-3735]) and somatic InDels were detected using GATK. Structure variants (SVs) and somatic CNVs were identified using BreakDancer ([@b35-mmr-13-05-3735])/CREST/SeekSV (self-method) and a self-method based on the SegSeq ([@b36-mmr-13-05-3735]) algorithm, respectively. Virus integration sites were identified using a self-method based on unmapped reads. The procedure also included purity estimation. Subsequently, filters were applied to obtain variant results of higher confidence and, based on which subsequent advanced analysis could be performed, ANNOVAR ([@b37-mmr-13-05-3735]) was used to annotate the variant results. Quality control was required at each stage of analysis to ensure clean data, alignment and variants. SIFT ([@b38-mmr-13-05-3735]) was used to assess the likely phenotypic effect of identified missense mutations. PolyPhen-2 ([@b39-mmr-13-05-3735]) analysis was performed to calculate the probability of an identified mutation as deleterious for disease pathogenesis.

Sequencing quality control
--------------------------

The raw reads, which contained the adapter sequence, a high content of unknown bases and low quality reads were removed prior to data analysis. The filtering steps were as follows: i) Removal of adapter reads. An adapter read was defined as a read that included the adapter bases, which were removed from the raw FASTQ data; ii) removal of low-quality reads. If more than half of the bases in a read were low-quality, defined as a base quality ≤5, the read was treated as a low-quality read and removed from the raw FASTQ data; iii) removal of reads in which unknown bases were \>10%. The \'clean reads\' were then used for downstream bioinformatics analysis. Finally statistical analysis was performed for data interpretation. The quality of the clean data is shown in [Figs. 1](#f1-mmr-13-05-3735){ref-type="fig"} and [2](#f2-mmr-13-05-3735){ref-type="fig"}.

Alignment quality control
-------------------------

The human genome build37 (hg19) was used as the reference genome in the present study. The whole-genome size of hg19 is 3,137,161,264 bp, whereas the effective size is 2,861,327,131 bp, following exclusion of the N bases, random regions, hap regions, and chromosome Un and chromosome M in the reference sequence. BWA was used to align the reference genome sequence for sequencing reads. Picard ([broadinstitute.github.io/picard](http://broadinstitute.github.io/picard)) was used to mark duplicated reads, which were redundant information produced by PCR.

Results
=======

Quality control of sequencing data
----------------------------------

To minimize the likelihood of systematic bias during sampling, two paired-end libraries with insert sizes of 500 bp were prepared for all samples and were subjected to whole-genome sequencing. Each library comprised four lanes, resulting in at least 30-fold haploid coverage for each sample. The raw image files were processed using the Illumina pipeline for base calling; default parameters and the sequences of each individual were generated as 90-bp-paired-end reads. A total of 144.3 GB raw sequence data were generated in a sequencing depth of \~30-fold. As shown in [Table II](#tII-mmr-13-05-3735){ref-type="table"}, comparison was performed between the raw and clean data, which were detected using whole-genome re-sequencing.

Alignment of quality control data
---------------------------------

The resulting calculated T2D genome consensus sequence covered 99.88% of the hg19 sequence. At a depth of 10-fold, the assembled consensus covered 97.98% of the reference genome using two paired-end reads. Thus, increased sequencing depth provided only a marginal increase in genome coverage. The alignment quality control results are shown in [Table III](#tIII-mmr-13-05-3735){ref-type="table"}. The distribution of per-base sequencing depth and cumulative depth distribution in the target regions are presented in [Fig. 3](#f3-mmr-13-05-3735){ref-type="fig"}. The data approximately followed a Poisson distribution, which showed that the exome-capturing target region was evenly sampled.

SNP analysis
------------

The genotype with the highest probability at a given locus was identified for each individual sequencing sample, and the consensus sequence of the sample was assembled and saved in CNS format. Using the consensus sequence, the polymorphic loci between the identified genotype and the reference were filtered and highlighted; this constitutes the high confident SNP dataset. Following the identification of the SNPs, ANNOVAR was used to perform annotation and classification.

The results revealed that 99.88% of the T2D SNPs were present in dbSNP, and there were 3,010 novel SNPs ([Table IV](#tIV-mmr-13-05-3735){ref-type="table"}). A total of 485 SNPs were screened, for which the SIFT score was \<0.05, and the PolyPhen score was \>0.85. These features suggested the pathological nature of the identified genetic variation. Of these 485 SNPs, 480 SNPs were found at exonic regions. The remaining SNPs were at exonic and splicing regions. All the SNPs were nonsynonymous genes. Compared with the 76 loci-containing genes causing an increased risk of T2D, 77 SNP loci were identified in 37 genes ([Table V](#tV-mmr-13-05-3735){ref-type="table"}).

InDel analysis
--------------

To detect the InDels, the present study used pair-end reads for gap alignment using the mpileup program in SAM tools. Following identification of the InDels, ANNOVAR was used for annotation and classification. Of the 642,189 identified InDels, the percentage that overlapped the dbSNP InDels was 68.52% ([Table VI](#tVI-mmr-13-05-3735){ref-type="table"}). The length distribution of the InDels in the whole target region and CDS region were also plotted ([Fig. 4](#f4-mmr-13-05-3735){ref-type="fig"}). The length distribution of InDel in CDS region indicated that peaks are present at 3, 6 and 9 bp length, the InDels with this periodicity are non-framenshift InDels, they have relatively small effect on the genome comparing with frameshift InDels.

SV, CNV and SNV analyses
------------------------

When aligning the paired-end reads, if a structure variation existed between the sequencing and the reference sequences, the requirements for pair-end alignment, also termed the PE map, may not be met; thus, these anomalous read pairs and soft clip reads were used in the present study to detect SVs. The resulting list of the SVs, that were detected at the whole-genome level are listed in [Table VII](#tVII-mmr-13-05-3735){ref-type="table"}.

The CNVs of each sample were detected using CNVnator. Following identification of the CNVs, ANNOVAR was used for annotation and classification ([Table VIII](#tVIII-mmr-13-05-3735){ref-type="table"}). Varscan was used to identify specific SNVs by simultaneously comparing read counts, base quality and allele frequency between the healthy individuals and patients with type 2 diabetes. Following identification of the SNVs, ANNOVAR was again used for annotation and classification ([Table IX](#tIX-mmr-13-05-3735){ref-type="table"} and [Figs. 5](#f5-mmr-13-05-3735){ref-type="fig"} and [6](#f6-mmr-13-05-3735){ref-type="fig"}).

Analyses of somatic InDels, somatic CNVs and somatic SVs
--------------------------------------------------------

In the sufficiently covered sites, the initial call was produced in the type 2 diabetes sample and then compared with the normal sample to detect evidence for the event. If there was no evidence to support the InDel event in the normal sample, the site was considered to be a putative somatic InDel. In total, there were 1,249 somatic InDels in 1,000 genome and dbSNP135, 688 in 1,000 genome specific, and 310 dbSNP135 specific. The results of the statistical analyses are provided in [Table X](#tX-mmr-13-05-3735){ref-type="table"}. The dbSNP rate was 42.19%, and without heterozygous.

Somatic CNVs correspond to relatively large regions of the genome, which are either deleted and fewer than the normal number, or duplicated and more than the normal number, on certain chromosomes. The results of the somatic CNVs analyses are shown in [Table XI](#tXI-mmr-13-05-3735){ref-type="table"}, and the somatic CNV overview is plotted in [Fig. 7](#f7-mmr-13-05-3735){ref-type="fig"}.

In the sufficiently covered sites, the initial call was produced in the type 2 diabetes sample and then compared with the normal sample to detect evidence for the event. If there was no evidence to support the SV event in the normal sample, this event was considered to be a putative somatic SV. The results of the somatic SV statistical analyses are presented in [Table XII](#tXII-mmr-13-05-3735){ref-type="table"}.

Discussion
==========

In the present study, whole-genome re-sequencing was performed with DNA pooling to investigate T2D in Chinese individuals. In total, 1.44 GB of raw data were generated in a short period of time. Among the data obtained, 3,010 novel SNPs and 120,703 novel InDels were found. In addition, 5,590 SVs, 4,713 CNVs and 13,049 SNVs were identified. There was a significant difference between cases and controls in 1,884 somatic CNVs and 74 somatic SVs. These findings improve current understanding of the genetic basis of T2D and offer insight for future investigations.

Among the identified genes, only rs734312 in WFS1 (with a SIFT score 0.02 and a PolyPhen score of 0.99) suggested a pathologic nature. It was also found that, even in the same genes, the associated loci were different in the present study. Although \>30 genetic susceptibility loci have been found in the comparison of 76 genes, the most frequently reported variants have small to moderate effects, and account for only a small proportion of the heritability of T2D, suggesting that the majority of inter-person genetic variation in this disease remains to be elucidated ([@b20-mmr-13-05-3735]).

KCNQ1 ([@b40-mmr-13-05-3735]), UBE2E2 and C2CD4A-C2CD4B ([@b19-mmr-13-05-3735]) have been identified as T2D susceptibility genes in three GWA scans in Japanese individuals. The combined analyses identified GLIS3, PEPD, FITM2-R3HDML-HNF4A, KCNK16, MAEA, GCC1-PAX4, PSMD6 and ZFAND3 as T2D loci reaching genome-wide significance in East Asia ([@b22-mmr-13-05-3735]). PTPRD and SRR have been identified as diabetes susceptibility loci in a study of a Han Chinese population ([@b2-mmr-13-05-3735]). In the present study, the SNP loci in the UBE2E2, PSMD6, ZFAND3 and SRR genes were not found. The results of the present study suggested that, in different patient populations, different genes may confer risks for diabetes, which may lead to more complex study designs for investigating the molecular pathogenesis of T2D.

A simple, but important observation was that DNA pooling provides a highly effective approach for examining the genetic underpinnings of common familial diseases. DNA pooling has been confirmed to be an effective and efficient method to select candidate susceptibility loci for follow-up by individual genotyping ([@b12-mmr-13-05-3735],[@b13-mmr-13-05-3735],[@b41-mmr-13-05-3735]). This indicates that the use of GWAS for a large number of cases and controls are technically and financially feasible. Additional findings of particular interest include the large-scale examination of possible genetic variants. The present study demonstrated novel, significant associations, including SNPs, CNVs, InDels and SNVs.

The present study indicated general recommendations, which are relevant to whole-genome re-sequencing using DNA pooling. The first recommendation is associated with the importance of careful quality control. In the present study, 144.3 GB of raw data were generated from the Illumina pipeline, which contained too many Ns or low quality bases. Small systematic differences can readily produce effects capable of obscuring true associations from being identified ([@b42-mmr-13-05-3735],[@b43-mmr-13-05-3735]). The present study implemented extensive quality control checks to minimize differences in the clean data, alignment and called variants.

The sequencing method used in the present study also resulted in sequence redundancy reaching an average of 35.70-fold. Thus, the consensus sequence accuracy was higher and particularly suitable for calling heterozygous alleles. Whole-genome re-sequencing with DNA pooling technologies is high throughput technique, as one hundred million DNA fragments can be sequenced in parallel on one chip. The Illumina HiSeq 2000 platform from Illumina used in the present study can provide up to 55 GB of high-quality data per day. In this regard, it was possible to undertake comprehensive assessments of the variants within the regions of interest using this high-throughput and time efficient method.

Thirty years ago, James V. Neel ([@b44-mmr-13-05-3735]) labeled T2D as \'the geneticist\'s nightmare\', describing the identification of genetic factors in T2D as challenging. Numerous investigations on candidate genes for T2D have been published; however, the various approaches, including high-throughput gene scanning and gene and pedigree analysis have not been entirely successful in identifying robustly replicating T2D-susceptibility loci. Ultimately, with large samples and worldwide collaboration, novel risk factors for diabetes are likely be identified using whole-genome re-sequencing technology.
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###### 

Clinical and biochemical characteristics of the 200 individuals recruited for re-sequencing.

  Characteristic                           ND (n=100)   T2D (n=100)
  ---------------------------------------- ------------ -------------
  Gender (males/females)                   63/37        55/45
  Age (years)                              60.1±11.8    5.4±0.6
  HbA1c (%)                                5.4±0.6      9.6±2.3
  Fasting plasma glucose (mmol/l)          4.9±0.6      11.4±3.9
  2-h OGTT-based plasma glucose (mmol/l)   6.0±0.4      13.5±2.1
  Body mass index (kg/m^2^)                24.0±1.5     31.7±5.0
  Waist circumference (cm)                 82.3±6.7     105.0±9.8
  Systolic blood pressure (mmHg)           125.0±7.0    152.0±9.0
  Diastolic blood pressure (mmHg)          84.0±5.0     92.0±6.0

Data are presented as the mean ± standard deviation for normally distributed traits, or the median. ND, non-diabetic; T2D, type 2 diabetes; OGTT, oral glucose tolerance test.

###### 

Quality control of sequencing data.

  Category                                      Data              Discarded reads (n)                     
  --------------------------------------------- ----------------- --------------------- ----------------- ------------
  Reads (n)                                     1,442,754,024                           1,367,776,414     
  Data size (bp)                                129,847,862,160                         123,099,877,260   
  N of fq1 (n)                                  41,142,158                              1,257,883         
  N of fq2 (n)                                  130,903,222                             3,072,470         
  GC of fq1 (%)                                 39.62--39.82                            39.47--39.7       
  GC of fq2 (%)                                 39.69--39.97                            39.56--39.78      
  Q20 of fq1 (%)                                96.16--97.06                            97.12--97.76      
  Q20 of fq2 (%)                                90.02--93.33                            93.88--95.97      
  Q30 of fq1 (%)                                90.13--92.30                            91.28--93.20      
  Q30 of fq2 (%)                                82.31--87.61                            86.04--90.21      
  Discarded reads associated with N                                                                       4,639,892
  Discarded reads due to low quality bases                                                                69,293,920
  Discarded reads associated with the adapter                                                             1,043,798
  Clean data/raw data (%)                                         94.80                                   

N, unknown bases more than 10%; Q20, recognition reliability of a base is equal to 99.0%; Q30, recognition reliability of a base is equal to 99.99%; fq1/2, file 1/2 of pair-end sequencing data; GC, the combination of bases G and C.

###### 

Alignment of quality control data.

  Whole-genome statistic         Value
  ------------------------------ -----------------
  Clean reads (n)                1,367,776,414
  Clean bases (bp)               123,099,877,260
  Mapped reads                   1,325,654,972
  Mapped bases (bp)              117,572,810,280
  Mapping rate (%)               96.92
  Unique reads (n)               1,271,136,561
  Unique bases (bp)              112,742,935,221
  Unique rate (%)                95.89
  Duplicate reads (n)            157,244,383
  Duplicate rate (%)             11.86
  Mismatch bases (bp)            481,007,764
  Mismatch rate (%)              0.41
  Average sequencing depth       35.70
  Coverage (%)                   99.88
  Coverage of at least 4X (%)    99.38
  Coverage of at least 10X (%)   97.98
  Coverage of at least 20X (%)   93.02

###### 

Single nucleotide polymorphism data.

  Category                               Value
  -------------------------------------- -----------
  Total (n)                              3,974,307
  1000 genome and dbSNP135 (n)           3,911,119
  1000 genome-specific (n)               1,712
  dbSNP135-specific (n)                  58,466
  dbSNP rate (%)                         99.88
  Novel (n)                              3,010
  Homozygous (n)                         475,874
  Heterozygous (n)                       3,498,433
  Synonymous (n)                         11,723
  Missense (n)                           9,897
  Stopgain (n)                           76
  Stoploss (n)                           31
  Exonic (n)                             21,422
  Exonic and splicing (n)                305
  Splicing (n)                           155
  ncRNA (n)                              97,213
  UTR5 (n)                               4,043
  UTR5 and UTR3 (n)                      14
  UTR3 (n)                               25,860
  Intronic (n)                           1,382,366
  Upstream (n)                           18,977
  Upstream and downstream (n)            582
  Downstream (n)                         22,165
  Intergenic (n)                         2,401,205
  Sorting intolerant from tolerant (n)   1,201
  Ti/Tv (n)                              2.1030
  dbSNP Ti/Tv (n)                        2.1043
  Novel Ti/Tv (n)                        1.1923

UTR, untranslated region; ncRNA, non-coding RNA; dbSNP, SNP database; Ti/Tv, ratio of transition to transversion.

###### 

List of 77 single nucleotide polymorphism loci in 37 genes identified in the present study.

  Gene      Function   Exonic function     dbSNP135      SIFT   PolyPhen2   Chr   Ref   Obs   Het/hom
  --------- ---------- ------------------- ------------- ------ ----------- ----- ----- ----- ---------
  ANK1      Exonic     Synonymous SNV      rs2304880                        8     G     A     Het
            Exonic     Synonymous SNV      rs2304873                              C     T     Het
            Exonic     Synonymous SNV      rs2304871                              G     A     Het
  ANKRD55   Exonic     Synonymous SNV      rs321775                         5     T     C     Het
            Exonic     Nonsynonymous SNV   rs321776      1      0                 C     T     Het
  BCAR1     Exonic     Synonymous SNV      rs3169330                        16    A     G     Hom
            exonic     Synonymous SNV      rs3743613                              C     T     Het
  GRB14     Exonic     Nonsynonymous SNV   rs61748245    0.27   0.009       2     A     T     Het
  CAMK1D    Exonic     Synonymous SNV      rs1757051                        10    C     G     Het
  TSPAN8    Exonic     Nonsynonymous SNV   rs1051334     1      0           12    A     C     Het
            Exonic     Synonymous SNV      rs2270587                              G     A     Het
            Exonic     Nonsynonymous SNV   rs3763978     0.08   0.981             C     G     Het
            Exonic     Nonsynonymous SNV   rs79443892    0.73   0                 C     T     Het
  THADA     Exonic     Nonsynonymous SNV   rs17031056    0.34               2     C     T     Het
            Exonic     Synonymous SNV      rs11899823                             A     G     Het
            Exonic     Synonymous SNV      rs13021894                             T     C     Het
  ADAMTS9   Exonic     Nonsynonymous SNV   rs17070905           0.057       3     C     T     Het
            Exonic     Nonsynonymous SNV   rs6787633            0                 G     C     Het
  BCL11A    Exonic     Synonymous SNV      rs7569946                        2     A     G     Hom
  KCNQ1     Exonic     Synonymous SNV      rs1057128                        11    G     A     Het
  HNF1A     Exonic     Synonymous SNV      rs1169289                        12    C     G     Het
            Exonic     Nonsynonymous SNV   rs1169288     0.09   0.052             A     C     Het
            Exonic     Synonymous SNV      rs2259820                              C     T     Het
            Exonic     Nonsynonymous SNV   rs2464196     0.06   0.053             G     A     Het
            Exonic     Nonsynonymous SNV   rs1169305     0.4    0.423999          A     G     Hom
  PRC1      Exonic     Nonsynonymous SNV   rs7172758     1      0           15    G     T     Hom
            Exonic     Synonymous SNV      rs2301826                              C     T     Het
  MADD      Exonic     Synonymous SNV      rs326214                         11    G     A     Het
            Exonic     Synonymous SNV      rs326217                               T     C     Het
            Exonic     Nonsynonymous SNV   rs1051006     0.19   0                 G     A     Het
            Exonic     Synonymous SNV      rs1017594                              T     C     Hom
  ADRA2A    Exonic     Synonymous SNV      rs1800038                        10    C     A     Het
  GLIS3     Exonic     Nonsynonymous SNV   rs806052      0.38   0           9     A     G     Hom
  SLC2A2    Exonic     Synonymous SNV      rs5398                           3     G     A     Het
  C2CD4B    Exonic     Nonsynonymous SNV   rs8040712     0.34   0           15    A     C     Het
  PTPRD     Exonic     Synonymous SNV      rs2279776                        9     C     G     Het
            Exonic     Synonymous SNV      rs2281747                              A     G     Het
            Exonic     Nonsynonymous SNV   rs35929428    0.09   0.016             G     A     Het
            Exonic     Synonymous SNV      rs7026388                              T     C     Het
            Exonic     Synonymous SNV      rs3763653                              G     A     Het
  C2CD4B    Exonic     Nonsynonymous SNV   rs8040712     0.34   0           15    A     C     Het
  GRB14     Exonic     Nonsynonymous SNV   rs61748245    0.27   0.009       2     A     T     Het
  GLIS3     Exonic     Nonsynonymous SNV   rs806052      0.38   0           9     A     G     Hom
  PEPD      Exonic     Synonymous SNV      rs17569                          19    G     A     Het
  FITM2     Exonic     Synonymous SNV      rs6073401                        20    T     C     Hom
  KCNK16    Exonic     Nonsynonymous SNV   rs11756091    0.03   0           6     G     T     Het
            Exonic     Synonymous SNV      rs11753141                             G     A     Het
            Exonic     Nonsynonymous SNV   rs1535500     0.12                     G     T     Het
            Exonic     Synonymous SNV      rs3734618                              A     G     Het
            Exonic     Synonymous SNV      rs3734619                              C     T     Het
  MAEA      Exonic     Synonymous SNV      rs1128427     0.13               4     T     C     Het
  PAX4      Exonic     Nonsynonymous SNV   rs712701      1      0           7     T     G     Het
  GCC1      Exonic     Synonymous SNV      rs3735644                        7     G     A     Het
            Exonic     Synonymous SNV      rs3735642                              A     G     Het
  KCNJ11    Exonic     Nonsynonymous SNV   rs5215        0.31   0.002       11    C     T     Het
            Exonic     Synonymous SNV      rs5218                                 G     A     Het
            Exonic     Nonsynonymous SNV   rs5219        0.36   0                 T     C     Het
  KCNQ1     Exonic     Synonymous SNV      rs1057128                        11    G     A     Het
  CDKAL1    Exonic     Synonymous SNV      rs9350269                        6     C     T     Het
            Exonic     Synonymous SNV      rs9465994                              G     A     Het
  HHEX      Exonic     Synonymous SNV      rs113121942                      10    G     A     Het
  SLC30A8   Exonic     Nonsynonymous SNV   rs13266634    0.04   0           8     C     T     Het
  WFS1      Exonic     Nonsynonymous SNV   rs1801212     1      0           4     G     A     Hom
            Exonic     Synonymous SNV      rs1801206                              C     T     Hom
            Exonic     Synonymous SNV      rs1801214                              C     T     Hom
            Exonic     Nonsynonymous SNV   rs734312      0.02   0.99              G     A     Het
            Exonic     Synonymous SNV      rs1046314                              G     A     Hom
  TCF7L2    Exonic     Nonsynonymous SNV   rs77961654    0.15   0.996       10    C     A     Het
  THADA     Exonic     Nonsynonymous SNV   rs17031056    0.34               2     C     T     Het
            Exonic     Synonymous SNV      rs11899823                             A     G     Het
            Exonic     Synonymous SNV      rs13021894                             T     C     Het
  ADAMTS9   Exonic     Nonsynonymous SNV   rs17070905           0.057       3     C     T     Het
            Exonic     Nonsynonymous SNV   rs6787633            0                 G     C     Het
  TSPAN8    Exonic     Nonsynonymous SNV   rs1051334     1      0           12    A     C     Het
            Exonic     Synonymous SNV      rs2270587                              G     A     Het
            Exonic     Nonsynonymous SNV   rs3763978     0.08   0.981             C     G     Het
            Exonic     Nonsynonymous SNV   rs79443892    0.73   0                 C     T     Het

SNV, single nucleotide variant; Chr, chromosome.; dbSNP, SNP database; Ref, reference genotype; Het, heterozygous; Hom, homozygous; Obs, observed.

###### 

Insertion/deletion data.

  Category                            Value
  ----------------------------------- ---------
  Total                               642,189
  1000 genome and dbSNP135            314,143
  1000 genome specific                81,476
  dbSNP135 specific                   125,867
  dbSNP rate (%)                      68.52
  Novel                               120,703
  Homozygous                          103,137
  Heterozygous                        539,052
  Frameshift insertion                120
  Non-frameshift insertion            88
  Frameshift deletion                 99
  Non-frameshift deletion             110
  Frameshift block substitution       0
  Non-frameshift block substitution   0
  Stopgain                            2
  Stoploss                            1
  Exonic                              415
  Exonic and splicing                 5
  Splicing                            77
  ncRNA                               16,036
  UTR5                                457
  UTR5 and UTR3                       3
  UTR3                                5,172
  Intronic                            225,732
  Upstream                            3,326
  Upstream and downstream             102
  Downstream                          4,324
  Intergenic                          386,540

SNP, single nucleotide polymorphism; UTR, untranslated region; dbSNP, dbSNP database; ncRNA, non-coding RNA.

###### 

Structure variant data.

  Category                  Value
  ------------------------- -------
  Total                     5,590
  Insertion                 348
  Deletion                  5,002
  Inversion                 14
  ITX                       122
  CTX                       104
  Exonic                    3
  Exonic and splicing       3
  Splicing                  7
  ncRNA                     133
  UTR5                      3
  UTR5 and UTR3             0
  UTR3                      9
  Intronic                  1,875
  Upstream                  15
  Upstream and downstream   0
  Downstream                31
  Intergenic                3,511

UTR, untranslated region; ncRNA, non-coding RNA; ITX, inversion; CTX, translocation.

###### 

Copy number variant data.

  Category                  Value
  ------------------------- ------------
  Total                     4,713
  Exonic                    930
  Exonic and splicing       0
  Splicing                  242
  ncRNA                     165
  UTR5                      1
  UTR5 and UTR3             0
  UTR3                      9
  Intronic                  1,026
  Upstream                  56
  Upstream and downstream   6
  Downstream                36
  Intergenic                2,242
  Amplification size        13,445,200
  Deletion size             84,646,400

UTR, untranslated region, ncRNA, non-coding RNA.

###### 

Single nucleotide variant statistics (healthy control, vs. T2D).

  Category                           Value
  ---------------------------------- --------
  Total                              13,049
  1000 genome and dbSNP135           12,655
  1000 genome specific               11
  dbSNP135 specific                  282
  dbSNP rate (%)                     99.14
  Novel                              101
  Hom                                0
  Het                                13,049
  Synonymous                         52
  Missense                           36
  Stopgain                           0
  Stoploss                           0
  Exonic                             88
  Exonic and splicing                0
  Splicing                           1
  ncRNA                              305
  UTR5                               15
  UTR5 and UTR3                      0
  UTR3                               112
  Intronic                           4,638
  Upstream                           73
  Upstream and downstream            0
  Downstream                         74
  Intergenic                         7,743
  Sorting Intolerant from Tolerant   7
  Ti/Tv                              2.1188
  dbSNP Ti/Tv                        2.1324
  Novel Ti/Tv                        1.0612

UTR, untranslated region; ncRNA, non-coding RNA; dbSNP, SNP database.

###### 

Somatic insertion and deletion statistics (healthy control, vs. T2D).

  Category                            Value
  ----------------------------------- -------
  1000 genome and dbSNP135            1,249
  1000 genome specific                688
  dbSNP135 specific                   310
  dbSNP rate (%)                      42.19
  Novel                               1,448
  Hom                                 3,695
  Het                                 0
  Frameshift insertion                0
  Non-frameshift insertion            0
  Frameshift deletion                 1
  Non-frameshift deletion             3
  Frameshift block substitution       0
  Non-frameshift block substitution   0
  Stopgain                            0
  Stoploss                            0
  Exonic                              4
  Exonic and splicing                 0
  Splicing                            1
  ncRNA                               93
  UTR5                                4
  UTR5 and UTR3                       0
  UTR3                                32
  Intronic                            1,242
  Upstream                            16
  Upstream and downstream             0
  Downstream                          27
  Intergenic                          2,276

UTR, untranslated region; ncRNA, non-coding RNA; dbSNP, SNP database.

###### 

Somatic copy number variant analysis (healthy control, vs, T2D).

  Category                  Value
  ------------------------- -----------
  Total                     1,884
  Exonic                    185
  Exonic and splicing       0
  Splicing                  21
  ncRNA                     41
  UTR5                      0
  UTR5 and UTR3             0
  UTR3                      6
  Intronic                  538
  Upstream                  14
  Upstream and downstream   0
  Downstream                17
  Intergenic                1,062
  Amplification size        1,372,716
  Deletion size             1,879,767

UTR, untranslated region; ncRNA, non-coding RNA.

###### 

Somatic structure variant statistics (healthy control, vs. T2D).

  Category                  Value
  ------------------------- -------
  Total                     74
  Insertion                 6
  Deletion                  58
  Inversion                 0
  ITX                       2
  CTX                       8
  Exonic                    0
  Exonic and splicing       0
  Splicing                  0
  ncRNA                     0
  UTR5                      0
  UTR5 and UTR3             0
  UTR3                      0
  Intronic                  24
  Upstream                  0
  Upstream and downstream   0
  Downstream                0
  Intergenic                50

UTR, untranslated region, ncRNA, non-coding RNA.

[^1]: Contributed equally
